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http://www.longevityandhealthspan.com/content/1/1/2RESEARCH Open AccessEvidence of a metabolic memory to early-life
dietary restriction in male C57BL/6 mice
Colin Selman* and Sarah HempenstallAbstract
Background: Dietary restriction (DR) extends lifespan and induces beneficial metabolic effects in many animals.
What is far less clear is whether animals retain a metabolic memory to previous DR exposure, that is, can early-life
DR preserve beneficial metabolic effects later in life even after the resumption of ad libitum (AL) feeding. We
examined a range of metabolic parameters (body mass, body composition (lean and fat mass), glucose tolerance,
fed blood glucose, fasting plasma insulin and insulin-like growth factor 1 (IGF-1), insulin sensitivity) in male C57BL/6
mice dietary switched from DR to AL (DR-AL) at 11 months of age (mid life). The converse switch (AL-DR) was also
undertaken at this time. We then compared metabolic parameters of the switched mice to one another and to
age-matched mice maintained exclusively on an AL or DR diet from early life (3 months of age) at 1 month,
6 months or 10 months post switch.
Results: Male mice dietary switched from AL-DR in mid life adopted the metabolic phenotype of mice exposed to
DR from early life, so by the 10-month timepoint the AL-DR mice overlapped significantly with the DR mice in
terms of their metabolic phenotype. Those animals switched from DR-AL in mid life showed clear evidence of a
glycemic memory, with significantly improved glucose tolerance relative to mice maintained exclusively on AL
feeding from early life. This difference in glucose tolerance was still apparent 10 months after the dietary switch,
despite body mass, fasting insulin levels and insulin sensitivity all being similar to AL mice at this time.
Conclusions: Male C57BL/6 mice retain a long-term glycemic memory of early-life DR, in that glucose tolerance is
enhanced in mice switched from DR-AL in mid life, relative to AL mice, even 10 months following the dietary
switch. These data therefore indicate that the phenotypic benefits of DR are not completely dissipated following a
return to AL feeding. The challenge now is to understand the molecular mechanisms underlying these effects, the
time course of these effects and whether similar interventions can confer comparable benefits in humans.
Keywords: Dietary restriction, Glucose tolerance, Insulin sensitivity, Dietary switch, C57BL/6 mice, Body composition,
Insulin, IGF-1, Metabolic memory, GlycemiaBackground
Dietary restriction (DR), a reduction in food intake with-
out malnutrition, is a well established experimental para-
digm that extends mean and maximum lifespan in many
animals [1]. In addition, chronic DR induces a range of
physiological benefits, including enhanced glucose toler-
ance and increased insulin sensitivity in rodents [2,3],
non-human primates [4,5] and humans [6,7]. However,
while the positive benefits of DR on healthy lifespan are
clear, it is unlikely that lifelong DR is a realistic or achiev-
able intervention for most human beings (for discussion,* Correspondence: c.selman@abdn.ac.uk
Integrative and Environmental Physiology, Institute of Biological and
Environmental Sciences, University of Aberdeen, Aberdeen, AB24 2TZ, UK
© 2012 Selman and Hempenstall; licensee Bio
the Creative Commons Attribution License (ht
distribution, and reproduction in any mediumsee [8,9]). What is perhaps more achievable are acute DR
interventions, particularly if these short-term periods of
DR can successfully elicit favorable metabolic effects and
particularly if those benefits are retained even following a
subsequent return to ad libitum (AL) feeding.
It is well established that acute DR improves a range of
metabolic parameters in both rodents [10-12] and humans
[13,14]. In mice, acute DR introduced either early (4 or
14 weeks of age, respectively) [15,16] or late in life (19 or
29 months of age, respectively) [17,18] rapidly alters
(within weeks) transcriptional profiles to those of mice
exposed to long-term DR. In addition, the converse switch
in older mice from DR back to AL feeding almost com-
pletely reverses the DR-induced gene expression profileMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Selman and Hempenstall Longevity & Healthspan 2012, 1:2 Page 2 of 11
http://www.longevityandhealthspan.com/content/1/1/2back to the AL control profile within 8 weeks [17,18]. Ini-
tiating DR in mid to late life generally extends lifespan in
rodents (for review see [1], and see also [19]) and delays
the onset of tumor incidence [17,20]. However, the life-
span extension effect appears to become less pronounced
the later in life that DR is initiated. Adult-onset DR also
decreased oxidative stress in rodents [21] and improved
glucose tolerance in rats [22]. Similarly, dietary switch
experiments (from AL to DR or from DR to AL) in mice
indicate that the beneficial effects of DR on certain mar-
kers of oxidative stress can be improved (or reversed, re-
spectively) within weeks following the switch [23,24].
Dietary shifts in adulthood from DR to AL (or from AL to
DR) in Drosophila [25,26] and rats [27], and dietary shifts
from AL to DR in adult mice [17] rapidly shifts the mor-
tality risk to the group that they are subsequently switched
to. In adult flies, at least, this reversal in mortality risk
through dietary switching can occur at any age [26]. It is
currently unclear in mice whether a shift from DR to con-
trol feeding also shifts the rate of ageing accordingly, al-
though this has been demonstrated clearly to be the case
in rats [27].
Interestingly, dietary switching in mid life from DR
to AL (or the converse AL to DR) in combination with
α-lipoic acid supplementation induced a metabolic mem-
ory effect in male rats, in that dietary switched animals
additionally supplemented with α-lipoic acid retained the
survival trajectory of the initial feeding regime [27]. In
contrast, rats shifted from 40% DR (initiated at 6 weeks of
age) to AL at 6 months of age had a greater median and
maximum (tenth percentile) lifespan compared to AL rats
[28], although no demonstrable effect on pathology, in-
cluding cardiomyopathy, nephropathy and various can-
cers, was reported relative to AL animals [29]. However,
the reverse shift from AL to DR at 6 months of age was as
effective as lifelong DR in attenuating the incidence of
these pathologies [29]. It is currently unclear whether
early-life exposure to DR can induce a lasting beneficial
metabolic effect in mice subsequently switched back to
AL feeding, that is, do animals retain a ‘metabolic mem-
ory’ to previous DR exposure? However, it has been
reported that rats shifted from 40% DR to AL at 6 months
of age remained significantly lighter than AL rats until
they reached approximately 700 days of age [28].
In the present study we examined whether a mid-life
dietary switch from AL to DR (AL-DR) or from DR to
AL (DR-AL) at 11 months of age (8 months of AL feed-
ing or 30% DR respectively) had any impact on a range
of metabolic parameters (for example, body mass, lean/
fat mass, glucose tolerance, insulin sensitivity) in male
C57BL/6 mice. Figure 1 shows a schematic of the experi-
mental design. Those mice switched from DR-AL at
11 months of age retained significantly enhanced glucose
tolerance relative to mice maintained exclusively on anAL diet. This improved glucose tolerance was retained
even 10 months following the switch. We also show that
mice switched from AL-DR at 11 months of age rapidly
adopt the glycemic profile of mice maintained on 30%
DR from early life (3 months of age). These data suggest
that mice switched from DR-AL in mid life retain a
long-term glycemic memory to previous DR exposure,
which maintains a long-term improvement in glucose
tolerance (and reduction in fasting insulin-like growth
factor 1 (IGF-1) levels) relative to mice maintained on
an AL diet throughout their life.
Results
Body mass, food intake, body composition
A significant difference in body mass (BM) was
observed between the experimental groups (AL, DR,
DR-AL, AL-DR) at 1 month (F = 39.224, P <0.001),
6 months (F = 52.744, P <0.001) and 10 months
(F = 53.715, P <0.001) following the dietary switch
(Figure 2A). By 1 month after the switch, both the
DR-AL and AL-DR groups were significantly lighter
than the AL mice, although both switch groups were
significantly heavier than the DR mice. At 6 months
post switch, the DR-AL switched mice were still sig-
nificantly lighter than the AL group but significantly
heavier than both the DR and AL-DR group. At this same
time, the BM of the AL-DR group had decreased to a level
similar to the DR group. Only by the 10-month timepoint
did the DR-AL mice attain a similar BM to the AL con-
trols, albeit they were still slightly lighter. Perhaps surpris-
ingly, given the time taken for the DR-AL mice to reach a
similar BM to the AL mice, these mice had a significantly
greater food intake relative to the AL mice at both
the 1-month and 6-month timepoints (Additional file 1).
Only by the final timepoint, at which BM was similar, was
food intake comparable between these two groups.
The lean mass (as a percentage of total body mass) dif-
fered significantly between groups at 1 month (F = 7.890,
P <0.001), 6 months (F = 3.421, P= 0.028) and 10 months
(F = 13.346, P <0.001) following the switch (Figure 2B).
At the 1-month timepoint, the AL-DR mice had a sig-
nificantly lower lean mass compared with all other
groups, with the DR-AL, AL and DR mice all being simi-
lar to one another. By 6 months post switch, the DR-AL
and AL-DR mice had intermediate, but not significantly
different, lean masses to the AL and DR mice. At this
same time, the DR group had a significantly greater lean
mass compared to AL mice. By the 10-month timepoint,
the DR-AL mice had a lean mass indistinguishable from
AL mice, with both DR-AL and AL mice having a sig-
nificantly lower lean mass relative to the AL-DR and
DR groups. Percentage fat mass also showed signifi-
cant groups effects at 1 month (F = 6.942, P = 0.001),
6 months (F= 6.228, P=0.002) and 10 months (F= 10.178,
30% DR initiated
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Figure 1 Schematic showing the experimental switch design. All mice (male C57BL/6) were fed ad libitum (AL) until 2.5 months of age and
then dietary restriction (DR) mice underwent a step-down DR regime resulting in 30% DR from 3 months of age onwards. The dietary switch was
initiated at 11 months of age, at which time the DR group had been on 30% DR for 8 months. The stippled lines denote the switch groups;
either AL to 30% DR (AL-DR) or 30% DR to AL (DR-AL). All metabolic measurements were determined at 1 month, 6 months and 10 months post
switch (equivalent to 12 months, 17 months and 21 months of age), except for fasting plasma insulin, fasting plasma insulin-like growth factor 1
(IGF-1) and insulin sensitivity, which were determined at 1 month and 10 months post switch only.
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DR-AL mice had a similar percentage fat mass to the AL
and DR mice. However, at this time the fat mass of the
AL-DR group was significantly greater than both the DR-
AL mice and DR mice, suggesting that there was a prefer-
ential loss of lean mass rather than fat mass following ini-
tiation of mid-life DR. By 6 months post switch, the DR-
AL group had an intermediate fat mass relative to all other
groups, with the AL mice having a significantly higher fat
mass compared to the DR and AL-DR mice. Following
10 months post switch, the DR-AL group had a similar fat
mass to the AL mice, although both of these groups were
significantly fatter than either the DR or the AL-DR mice.
Glucose homeostasis
In terms of fed blood glucose (Figure 3A), the dietary
switch groups rapidly adopted the profiles of the
groups they were switched to in mid life, that is, DR-
AL and AL were comparable to one another but signifi-
cantly different to the comparable DR and AL-DR
mice within 1 month of the switch (1 month:
F = 13.134, P <0.001; 6 months: F = 21.298, P <0.001;
10 months: F = 15.890, P <0.001). Significant group effects
on glucose tolerance were also observed at 1 month
(F= 10.313, P <0.001), 6 months (F= 18.739, P <0.001)
and 10 months (F= 20.746, P <0.001) following the diet-
ary switch (Figure 3B). At 1 month post switch, the DR-
AL group had a similar glucose tolerance to AL mice. Atthis same time, the AL-DR mice had an intermediate glu-
cose tolerance compared to all other groups, with the
early-life DR mice having a significantly greater glucose
tolerance relative to the DR-AL and AL mice. At 6 months
post switch, the DR-AL mice had a significantly enhanced
glucose tolerance compared to AL mice. In addition, the
DR-AL mice had a glucose tolerance that was not signifi-
cantly different to the early-life DR group. At this same
time the AL-DR mice had a significantly better glucose
tolerance compared to both the AL and DR-AL mice. By
the 10-month timepoint, the DR-AL mice retained their
significantly enhanced glucose tolerance compared to AL
mice, although improved glucose tolerance was observed
in the DR and AL-DR mice compared to both AL and
DR-AL mice at this time. For comparative purposes, the
glucose tolerance curves are also shown in Figure 3C-E at
the 1-month, 6-month and 10-month timepoints, respect-
ively. This data clearly indicates the significantly improved
glucose tolerance of the DR-AL group relative to the AL
group at the 6-month and 10-month timepoints. Fasting
blood glucose levels were not significantly different be-
tween any groups at either the 1-month (F= 1.586,
P=0.210) or 6-month timepoints (F= 1.943, P=0.141).
However, by 10 months a significant difference between
groups was detected (F = 3.639, P = 0.024), with the
fasting blood glucose of the AL mice being signifi-
cantly elevated (P = 0.021, post hoc Tukey) relative to
the AL-DR mice.
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Figure 2 Body mass and body compositional changes following dietary switches in male C57BL/6 mice. Body mass (A), percentage lean
mass (B) and percentage fat mass (C) in ad libitum (AL), dietary restriction (DR), AL-DR and DR-AL mice at 1 month, 6 months and 10 months
post switch. Groups sharing the same letter within the same timepoint (that is, 1 month, 6 months or 10 months) were not significantly different
to one another. Results are reported as mean± standard error of the mean (SEM), with P <0.05 regarded as statistically significant. N = 7 to 10 per
group.
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Figure 3 Fed blood glucose levels and glucose tolerance following dietary switches in male C57BL/6 mice. Fed blood glucose levels (A)
and glucose tolerance (B), determined by area under the curve (AUC), in ad libitum (AL), dietary restriction (DR), AL-DR and DR-AL mice at
1 month, 6 months and 10 months post switch. Groups sharing the same letter within the same timepoint (that is, 1 month, 6 months or
10 months) were not significantly different to one another. Results are reported as mean± standard error of the mean (SEM), with P <0.05
regarded as statistically significant. In addition, glucose tolerance curves (C-E) are shown for all groups at 1 month, 6 months or 10 months post
switch, respectively. N = 7 to 10 per group.
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and insulin sensitivity
The effects of dietary switching on fasting plasma insulin,
fasting plasma IGF-1 and insulin sensitivity (HOMA2)
were determine at 1 month and 10 months post switch.
Despite fasting plasma insulin levels being lower in DR
and DR-AL mice 1 month following the dietary switch
compared to AL and AL-DR mice (Figure 4A), no signifi-
cant group effect was detected (F= 0.971; P=0.426). How-
ever, by the 10-month timepoint a significant group effect
was seen (F= 5.888; P=0.004), with the DR-AL and ALmice having significantly elevated fasting insulin levels
relative to the AL-DR group. The early-life DR group also
had lower fasting insulin levels compared to both the DR-
AL and AL mice at this time, although this did not quite
reach statistical significance when using post hoc Tukey
tests. A significant group effect on fasting plasma IGF-1
levels was observed at both 1 month (F= 9.274, P= 0.001)
and 10 months (F = 6.764, P = 0.002) post switch
(Figure 4B). At the 1-month timepoint, no differences
were detected between the DR-AL, AL and DR mice, al-
though the AL-DR group had significantly lower fasting
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Figure 4 Fasting plasma insulin, fasting plasma insulin-like growth factor 1 (IGF-1) and insulin sensitivity following dietary switches in
male C57BL/6 mice. Fasting plasma insulin levels (A), fasting plasma IGF-1 levels (B) and insulin sensitivity (C), determined using the updated
homeostatic model assessment (HOMA2) model in ad libitum (AL), dietary restriction (DR), AL-DR and DR-AL mice at 1 month, 6 months or
10 months post switch. Groups sharing the same letter within the same timepoint (that is, 1 month, 6 months or 10 months) were not
significantly different to one another. Results are reported as mean± standard error of the mean (SEM), with P <0.05 regarded as statistically
significant. N = 7 to 10 per group.
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following the switch, both switch groups had significantly
lower IGF-1 levels relative to AL mice, with the early-life
DR group having an intermediate IGF-1 level relative to
all other groups. Finally, insulin sensitivity (Figure 4C) at
1 month post switch was significantly increased in the
DR-AL and early-life DR mice relative to AL mice
(F= 4.602, P=0.013). Insulin sensitivity in the AL-DR
mice at this time was intermediate to all other groups.
However, by the 10-month timepoint, the DR-AL mice
had comparable insulin sensitivity to the AL group. The
AL-DR mice at this time had significantly greater insulin
sensitivity than both the AL and DR-AL mice (F= 4.281,
P=0.016). Perhaps surprisingly, the early-life DR group
had an intermediate insulin sensitivity profile relative to
all other groups at this time.
Discussion
This study examined the effects of a mid life (11 months
of age) dietary switch from 30% DR to AL (DR-AL) feed-
ing or from AL feeding to 30% DR (AL-DR) on a range
of metabolic parameters and compared these to animals
maintained exclusively on AL feeding or 30% DR from
early life (3 months of age). In particular we were inter-
ested in whether the experience of early-life DR could
confer metabolic benefits in mice subsequently switched
back to an AL diet, that is, does a metabolic memory
exist? Currently, there is very little experimental evidence
to suggest that mice retain a metabolic memory to previ-
ous DR exposure. A dietary shift from AL-DR in adult flies
[25,26], rats [27] and mice [17] resulted in animals rapidly
adopting the decreased mortality risk of long-term DR
animals. The converse shift in flies [25,26] and rats [27]
has also been shown to increase the mortality risk to that
of AL animals. In addition, the shift from DR-AL rapidly
reverses the majority of the transcriptional changes
induced by long-term DR [17,18]. In contrast to the studies
above [25-27], a dietary shift from DR-AL in rats demon-
strated a benefit to early-life DR on lifespan [28], that is,
the DR-AL rats lived significantly longer than animals
maintained on AL feeding throughout their life. Similar
evidence of a metabolic memory to previous DR exposure
was also reported in a second rat study [27]. Interestingly,
this study showed that those animals switched from DR-
AL (or AL-DR) at either 6 months or 12 months only
retained the survival trajectory of the initial feeding regime
when they were additionally dietary supplemented with α-
lipoic acid [27].
In terms of BM, perhaps surprisingly the mice in the
current study shifted from DR and back to AL feeding
(DR-AL) remained lighter that AL mice at 1 month and
6 months post switch, only reaching a similar BM to AL
mice 10 months after the dietary switch. In addition,
those animals switched to DR in mid life (AL-DR), werestill heavier than the early-life DR group following
1 month post switch, although by the 6-month time-
point their BM was indistinguishable from the DR
group. While it has been reported that a shift back to
AL feeding from acute DR (≤ 100 day duration) can in-
crease BM back to AL levels within 50 days in MF1 mice
[30], we observed a far slower response in agreement
with studies in rats [28] and in other strains of mice
[19]. While the shift from DR-AL feeding induces hyper-
phagia, this response is suggested as being highly transi-
ent (1 to 5 days), after which food intake (FI) levels (and
BM) return to AL levels [30,31]. However, in rats the
mass-adjusted FI of animals switched from DR-AL was
elevated until the switch animals reached the similar BM
of AL rats, around 18 months post switch [28]. In our
study, food intake in the DR-AL group was significantly
greater at the 1-month and 6-month timepoints relative to
AL mice. This hyperphagic response was not observed in
the DR-AL group at the final timepoint, at a time when
no BM differences were observed between the DR-AL and
AL mice. Our data, as does the rat data [28], suggests that
hyperphagia following DR is maintained until BM reaches
the levels of AL animals. A similar prolonged hyperphagic
response was also reported in male C57BL/6 mice follow-
ing a dietary shift from DR-AL, although interestingly this
was not observed in female mice [32]. Significant differ-
ences in body composition (percentage lean and fat mass)
were observed between groups throughout the timecourse
of this experiment. At the 1-month timepoint, percentage
lean mass was lowest, but percentage fat mass highest, in
the AL-DR mice. This suggests that this group preferen-
tially maintained their fat mass relative to lean mass fol-
lowing the mid-life switch to DR. The reasons for this are
unclear, although may be a temporal stress response to an
unpredictable food resource, as previously suggested [33].
Interestingly, this response after 1 month of 30% DR may
be age specific, as 3 weeks of 30% DR had no effect
on either lean or fat mass in young (15 week old)
male C57BL/6 (and DBA/2) mice [10], although it
should be noted that this paper used a different
method to control for BM differences between groups
than used in the current manuscript. It was only after
10 months post switch that the DR-AL and AL-DR
groups mirrored the body composition profiles of the
early-life AL and DR groups, respectively.
In agreement with previous studies examining short-
term DR in young mice [10-12], and in contrast to the
body mass and body composition effects observed, mice
switched from AL-DR rapidly adopted the improved glu-
cose tolerance of the DR group. This similarity in glu-
cose tolerance to mice exposed to DR from early life,
and significant improvement relative to the AL mice,
was maintained at both 6 months and 10 months post
switch. These data indicate that DR, even when initiated
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the glycemic profile of mice, and support previous data
in both rodents [22] and humans [13,14,34]. In mice
switched from DR-AL, glucose tolerance was not statisti-
cally different to AL mice at 1 month post switch. How-
ever, by 6 months and 10 months post switch this group
had a significantly enhanced glucose tolerance relative to
the AL mice, despite having very similar body mass,
body composition and fasting insulin levels to AL mice
at the 10-month timepoint. These data suggest that male
C57BL/6 mice retain a glycemic memory to previous DR
feeding that maintains a long-term benefit to glucose
tolerance that is independent of body composition and
fasting insulin levels. In support, Cameron et al.[32] also
reported that male C57BL/6 mice switched from AL to
DR (12 months of age) and then back to AL (17 months
of age) had improved glucose tolerance relative to life-
long AL mice 5 months after switching back to AL feed-
ing. The effect of dietary switching on fasting insulin
levels and insulin sensitivity were less clear in our study,
although the AL-DR had significantly lower fasting insulin
levels and increased insulin sensitivity relative to both the
DR-AL and AL mice 10 months post switch. Improved
glucose tolerance following late-life initiation in DR has
previously been reported in rats [22], although significant
differences in serum insulin levels were only seen follow-
ing glucose challenge [22]. Fasting IGF-1 levels, which we
have previously shown respond rapidly to early-life DR in
mice [10], were also decreased significantly following mid-
life DR, with the AL-DR group having lower IGF-1 levels
compared to all other groups. This suggests that dietary
switches to DR both in early life [10] and in mid life can
elicit similar rapid changes in IGF-1 levels in mice, and
that IGF-1 appears more responsive than insulin to DR
[10]. After 10 months post switch, while fasting insulin
and IGF-1 levels were reduced and insulin sensitivity
increased in the AL-DR group relative to AL mice, only
IGF-1 levels were reduced in the DR-AL group compared
to the AL group. The exact reasons for this uncoupling in
the response of insulin and IGF-1 to mid-life dietary shifts
back to AL feeding are currently unclear. We suggest that
the precise role of insulin and IGF-1 signaling following
mid-life dietary switches now requires further investiga-
tion, as late-onset DR in rats improved glucose tolerance
without having any impact on insulin signaling within
skeletal muscle [22]. In addition, while many studies have
examined the transcriptional response to DR in many tis-
sues (see for example [15,16,18,35,36]), information on
exactly how DR impacts on pancreatic and β-cell function
is currently lacking. We suggest that with our data dem-
onstrating clear evidence of a glycemic memory to previ-
ous DR exposure in mice, it is now critical to examine the
molecular responses in the pancreas to DR and to mid-life
dietary switches.Conclusions
In the present study we demonstrate that mid-life DR
(initiated from 11 months of age) rapidly improves sev-
eral metabolic parameters to those of mice exposed to
DR from early life. In addition, we also provide evidence
of the existence of a glycemic memory to previous DR
exposure that confers later-life benefits to mice in terms
of improved glucose tolerance. Surprisingly, this effect was
not associated with alterations in fasted plasma insulin
levels or insulin sensitivity (as determined by HOMA2);
although it was associated with significantly lower fasting
plasma IGF-1 levels. While the idea of a metabolic mem-
ory following DR has previously been voiced [37] follow-
ing studies in rats [27,28], our study, and that of Cameron
et al. [32], give the strongest support yet that a metabolic
memory exists in mice. These findings suggest that the
benefits to previous DR are maintained at the level of the
phenotype, despite apparent rapid reversals in transcrip-
tion following similar dietary switches in mice [17,18,38].
Similar directional dietary shifts in rats extend lifespan
relative to AL controls [28], and so enhanced glucose tol-
erance underlying this lifespan extension is certainly
plausible. The challenge now is to identify the biochemical
and signaling processes that underlie this improved glu-
cose tolerance, including how early-life DR may impacts
on processes such as DNA methylation and post-
translational modifications to histones and proteins
[39-41]. It is unequivocal that impaired glucose tolerance
is associated with a range of age-associated pathologies in
humans [42-44]. Therefore, understanding how early-life
DR improves later-life glucose tolerance may give useful
insights in to understanding, and ultimately intervening,
in associated age-related pathologies.
Methods
Mice
Inbred male C57BL/6 mice were purchased from a com-
mercial breeder (Charles River Laboratories, Margate,
UK) at 1 month of age. Mice were maintained in pairs
from 2 months of age onwards in polycarbonate shoebox
cages (48 × 15 × 13 cm), with ad libitum access to water
and standard chow (D12450B, Research Diets Inc., New
Brunswick, NJ, USA; protein 20 kcal%, carbohydrate
70 kcal%, fat 10 kcal%). Mice were maintained on a 12 h
light/12 h dark cycle (lights on 7.00 am to 7.00 pm) at a
housing temperature of 22 ± 2 °C. At 2.5 months of age,
weight-matched pairs were assigned to the AL or dietary
restricted (DR) groups, with no difference in body mass
observed between groups at this time (AL = 25.1 ± 0.5 g,
DR= 25.3 ± 0.5 g; F = 3.354, P= 0.137). The DR protocol
used in this study followed exactly a previously described
protocol [10,15]. In brief, daily food intake of the DR
mice was reduced to 90% of the AL intake at 2.5 months
of age, reduced to 80% of AL intake at 2.75 months of
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3 months of age onwards, that is, 30% DR relative to AL
controls. Food intake of AL mice was measured weekly
(± 0.01 g) and 30% DR calculated from the AL mice in-
take over the preceding week. DR and AL-DR mice were
fed daily between 4.30 pm to 5.30 pm. At 11 months of
age, mice randomly selected from the 30% group were
dietary switched to AL feeding (that is, DR-AL) and
mice from the AL group were switched to 30% DR (that
is, AL-DR). See Figure 1 for a schematic of the experi-
mental design, indicating the resulting four groups (AL,
DR, DR-AL, AL-DR) following the switch and the time-
points at which the metabolic measurements were col-
lected (1 month, 6 months and 10 months post switch).
A significant difference in body mass was observed be-
tween the AL and DR mice immediately before the
switch (F = 94.526, P <0.001). However, using post hoc
Tukey tests we show that no difference in body mass
was observed at this time between the AL mice and
those mice subsequently switched AL-DR (34.3 ± 0.8 g
and 34.5 ± 0.6 g, respectively), or between DR mice and
those animals subsequently switched from DR-AL mice
(25.5 ± 0.4 g and 25.1 ± 0.3 g, respectively). Note that the
mice dietary switched at 11 months of age were switched
immediately to full AL feeding or 30% DR, rather than
undergoing any incremental step-down (or step-up) in
food intake.
Body mass, food intake and body composition
Body mass and food intake for all groups was measured
at 1 month, 6 months and 10 months post switch using
an analytical balance (± 0.01 g). Body composition (lean
and fat mass) was also determined at 1 month, 6 months
and 10 months post switch using dual-energy X-ray ab-
sorptiometry (DXA; Lunar PIXImus mouse densitom-
eter, GE Medical Systems, Slough, UK). In brief, mice
were weighed and subsequently anaesthetized using 3.5%
isoflurane (Henry Schein Animal Health, Dumfries, UK)
by inhalation for the duration of the scanning period
(approximately 3.5 per min). Lunar PIXImus 2.10 soft-
ware was used to calculate percentage lean mass and
percentage fat mass in the region of interest (defined as
the subcranial body, as recommended by the manufac-
turer) using a previously described protocol [45].
Glucose homeostasis
Fed blood glucose was determined in AL and DR-AL
mice at 11.00 am and in DR and AL-DR mice at
6.30 pm, as described elsewhere [10]. Glucose tolerance
was determined at 1 month, 6 months and 10 months
post switch following an overnight fast (7.00 pm to
8.00 am), using a previously described protocol [10]. For
both fed blood glucose and glucose tolerance tests, DR
mice were fed at approximately 3.00 pm on the dayimmediately prior to testing [10]. In brief, mice were
weighed, injected intraperitoneally with 20% D-glucose
(2 g/kg) and then blood glucose levels were collected from
tail vein samples and read on a glucometer (OneTouch
Ultra, Lifescan, High Wycombe, UK) as previously
described [46]. Glucose tolerance is expressed as the
area under the curve over a 120-min period follow-
ing the intraperitoneal injection of D-glucose.
Fasting plasma insulin levels, IGF-1 levels and insulin
sensitivity
At 1 month and 10 months post switch, mice from all
four groups were fasted overnight, and then weighed
and killed by cervical dislocation. Venous trunk blood
was collected and the resultant plasma stored at −80 °C.
Fasting plasma insulin levels were measured using a
mouse insulin ELISA kit (Crystal Chem Inc., Downers
Grove, IL, USA). Insulin sensitivity was estimated using
the updated homeostatic model assessment (HOMA2)
model [47]. In brief, this model generates approximate
values of insulin sensitivity derived from fasting glucose
and fasting insulin levels. Although this model has not
been validated formally in mice, it has been used widely
in experimental studies to determine insulin sensitivity
and insulin resistance (see for example [10,48-50]. Fast-
ing plasma IGF-1 levels were determined using a mouse
IGF-1 ELISA kit (R&D Systems Europe Ltd., Abingdon,
UK). All experiments were carried out following local
ethical review (University of Aberdeen, UK), under a li-
cense from the UK Home Office and followed the ‘prin-
ciples of laboratory animal care’ (NIH Publication No.
86–23, revised 1985).
Statistical analysis
All analyses were performed using SPSS v.18 (SPSS Inc.,
Chicago, IL, USA) and GraphPad Prism v.5 (GraphPad
Inc., La Jolla, CA, USA) software. Data were checked for
normality using the Shapiro-Wilks test. Data was ana-
lyzed using one-way analysis of variance (ANOVA) with
post hoc Tukey tests to determine differences between
groups within a timepoint. Results are reported as
mean ± standard error of the mean (SEM), with P <0.05
regarded as statistically significant in all cases. Groups
sharing the same letter within a timepoint (that is,
1 month, 6 months or 10 months) were not significantly
different to one another. Sample size was 7 to 10 per
group throughout.
Additional file
Additional file 1: Title: Mean (± SEM) daily food intake per cage at
1 month, 6 months or 10 months post switch in ad libitum (AL)
mice and mice switched from 30% dietary restriction (DR) to AL
(DR-AL) feeding. Description: The DR-AL mice had significantly greater
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